AstraZeneca vision:

To be a worldwide biopharmaceutical business delivering great medicines to patients through

innovative science and excellence in development and exploitation.

Mission: to push the boundaries of science to deliver life changing medicines

AstraZeneca strategy is targeted on innovation with 3 strategic priorities:

Achieve scientific leadership delivering the complete potential of our
distinctive combination of discovery and development strengths in tiny molecule and
biologics, immunotherapies and macromolecule engineering. This includes progressing
our phase II clinical trial pipeline (which has the potential to double our phase III clinical
trial pipeline by 2016), and launching a gradual flow of specialty
care product, equalization our historic strength in medical care.
Return to growth focusing our industrial experience on key wellness franchises and
high potential marketplaces.
Be a good place to figure building a culture that's science and patient-focused, agile and
high-performing, that retains and attracts potential consumer. This includes simplifying
our organization and up production whereas making aspirated, cooperative work
surroundings.

Global marketing of new medicine
Ability to deliver the potential of existing and future merchandise through the
facility and reach of a combined world sales and selling resource
Widespread category coverage in key medical
care areas, like vessel and disease, owing to complementary nature of merchandise
Major medical care presence, significantly in canal, vessel and metabolic
process drugs
Leading position in a very variety of specialist/hospital markets, together
with medicine and anesthesia


Research and development of AstraZeneca
AstraZeneca is now the second largest investor in research and development in the
pharmaceutical industry world-wide.

AstraZeneca has been able to dramatically increase the scale of the research and
development, providing more manpower, improved, shared technology and a larger
number of laboratories.

Globally, our R&D focus is on six key therapeutic areas where we believe our skills and
experience can make the most difference: cancer, infection, cardiovascular diseases and
diabetes, gastrointestinal, neuroscience and respiratory.



Partnering, collaborations and open innovation remain key to pushing boundaries
of science
We are driving science through collaborations, more than 90 partnerships in the last three
years.
To deliver through the next generation of medicines, work in alliance management to
achieve the best science and medication thats happening elsewhere.
The quality of transformation across our business underpins our confidence in
AstraZeneca longer term prospect
Accessing through an open innovation website , Advancing research together.